ReviewMolecular cancer2026
Spatial multi-omics analyses of the tumor immune microenvironment: advances and novel therapeutic avenues.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The tumor immune microenvironment (TIME) is a spatially organized ecosystem in which the distribution and interaction of cellular and molecular components have a significant impact on disease progression and therapeutic response. Traditionally, bulk analyses have failed to capture the critical spatial context governing these dynamics. The latest breakthroughs in spatial multi-omics technologies, including spatial transcriptomics, proteomics and metabolomics, have completely transformed our ability to characterize the TIME at unprecedented resolution. These advanced platforms enable precise mapping of immune cell distribution, reconstruction of intercellular communication networks, and identification of pattern structures such as tertiary lymphoid structures (TLS). We reviewed the current experimental methods of spatial omics and highlights how their applications provide novel insights into tumor biology. We further discussed how insights from spatial profiling could inform the development of novel therapeutic strategies aimed at actively remodeling the TIME, provide information for prognosis prediction, and shape responses to treatments such as immunotherapy. Despite the challenges in standardization and clinical translation, spatial multi-omics provides an indispensable dimension for understanding tumor immunobiology, paving the way for more precise tumor diagnosis, prognosis and treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.